Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.

Moreau-Marquis, Sophie; O'Toole, George A; Stanton, Bruce A

Moreau-Marquis, Sophie; O'Toole, George A; Stanton, Bruce A.

Affiliation

Moreau-Marquis S; Department of Physiology, Dartmouth Medical School, Hanover, NH 03755, USA. Sophie.Marquis@Dartmouth.edu

Am J Respir Cell Mol Biol ; 41(3): 305-13, 2009 Sep.

Article in En | MEDLINE | ID: mdl-19168700

Subject(s)

Anti-Bacterial Agents; Biofilms/drug effects; Cystic Fibrosis/microbiology; Iron Chelating Agents; Pseudomonas Infections/drug therapy; Tobramycin; Anti-Bacterial Agents/pharmacology; Anti-Bacterial Agents/therapeutic use; Benzoates/pharmacology; Benzoates/therapeutic use; Cells, Cultured; Conalbumin/pharmacology; Conalbumin/therapeutic use; Deferasirox; Deferoxamine/pharmacology; Deferoxamine/therapeutic use; Epithelial Cells/microbiology; Humans; Iron Chelating Agents/pharmacology; Iron Chelating Agents/therapeutic use; Tobramycin/pharmacology; Tobramycin/therapeutic use; Triazoles/pharmacology; Triazoles/therapeutic use; United States; United States Food and Drug Administration

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pseudomonas Infections / Tobramycin / Iron Chelating Agents / Biofilms / Cystic Fibrosis / Anti-Bacterial Agents Limits: Humans Country/Region as subject: America do norte Language: En Journal: Am J Respir Cell Mol Biol Journal subject: BIOLOGIA MOLECULAR Year: 2009 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google